| Q33832651 | Antiestrogens--tamoxifen, SERMs and beyond |
| Q37585095 | Biological determinants of endocrine resistance in breast cancer |
| Q37254804 | Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer |
| Q36902056 | Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. |
| Q92578222 | Dynamic interactions between the extracellular matrix and estrogen activity in progression of ER+ breast cancer |
| Q37240697 | ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer |
| Q36614997 | Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer |
| Q37340411 | Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure |
| Q24813627 | Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer |
| Q24810287 | Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way? |
| Q33281087 | Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer |
| Q33612070 | Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation |
| Q37346786 | Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix |
| Q34022694 | Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer |
| Q92240915 | Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression |
| Q36109381 | Evidence for Homodimerization of the c-Fos Transcription Factor in Live Cells Revealed by Fluorescence Microscopy and Computer Modeling |
| Q36029524 | HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance |
| Q35060075 | Identification of novel Ras-cooperating oncogenes in Drosophila melanogaster: a RhoGEF/Rho-family/JNK pathway is a central driver of tumorigenesis |
| Q34452797 | Integrated quantitative analysis of the phosphoproteome and transcriptome in tamoxifen-resistant breast cancer |
| Q64884689 | KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function. |
| Q37467189 | Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. |
| Q35571726 | Macrophage-elicited loss of estrogen receptor-α in breast cancer cells via involvement of MAPK and c-Jun at the ESR1 genomic locus. |
| Q34398485 | Mayven induces c-Jun expression and cyclin D1 activation in breast cancer cells |
| Q36851417 | Mechanisms of Endocrine Resistance in Breast Cancer |
| Q36589865 | Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. |
| Q24675637 | Multiple kinase cascades mediate prolactin signals to activating protein-1 in breast cancer cells |
| Q91794639 | New insights into acquired endocrine resistance of breast cancer |
| Q35572443 | Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways |
| Q55342026 | Overcoming endocrine resistance in hormone receptor-positive breast cancer. |
| Q45494068 | PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells |
| Q93186271 | Pathways to Endocrine Therapy Resistance in Breast Cancer |
| Q35022183 | Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes Twist1 protein and promotes breast cancer cell invasiveness |
| Q37690705 | Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy |
| Q35121907 | Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1/2-mediated signals to c-fos |
| Q33555787 | Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas |
| Q26783076 | Roles for miRNAs in endocrine resistance in breast cancer |
| Q55242399 | Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity. |
| Q36621886 | Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines |
| Q38667106 | Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell context. |
| Q33670029 | Sustained c-Jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation |
| Q49803828 | The Role of the Estrogen Pathway in the Tumor Microenvironment. |
| Q36336601 | The changing role of ER in endocrine resistance |
| Q40720904 | The dynamic structure of the estrogen receptor |
| Q34405377 | Transcriptional regulation of hTREX84 in human cancer cells |
| Q30763243 | Transcriptional regulation prediction of antiestrogen resistance in breast cancer based on RNA polymerase II binding data |
| Q24813647 | Understanding endocrine resistance: the critical need for sequential samples from clinical breast cancer and novel in vitro models |
| Q35828457 | c-Jun N-terminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression |
| Q52691493 | c-Jun/AP-1 overexpression reprograms ERα signaling related to tamoxifen response in ERα-positive breast cancer. |